Exploring COVID-19 Vaccination & Infection in Patients With MM
The ASH Research Collaborative developed the COSMIC study to address the risks severe COVID-19 complications pose to patients with multiple myeloma.
Jan 29, 2025
MEETING BRIEF
ASH 2024 – MM
The latest news from ASH 2024 focused on multiple myeloma (MM) including abstracts, features, and helpful conference information.
Treatment Delays Progression, Improves Outcomes in High-Risk Smoldering MM
Treatment Delays Progression, Improves Outcomes in High-Risk Smoldering MM
Monoclonal antibody delayed progression to MM, improved PFS, ORR, and OS, and was well tolerated in high-risk SMM, supporting early intervention over monitoring.
Key Findings from ASH: Survival Benefits Highlighted in High-Risk Smoldering Myeloma Study & More
Key Findings from ASH: Survival Benefits Highlighted in High-Risk Smoldering Myeloma Study & More
This year’s ASH was exceptionally busy, with overlapping sessions, including three back-to-back myeloma talks. Key studies showcased practice-changing findings.
Promising Results From iMMagine-1 Trial: Advancement for Relapsed/Refractory MM
Promising Results From iMMagine-1 Trial: Advancement for Relapsed/Refractory MM
iMMagine-1 phase 2 trial shows 97% response, 62% complete response in relapsed/refractory myeloma, with strong safety and promising 2026 launch.
Circulating Plasma Cells Predict Poor Survival in Multiple Myeloma
Circulating Plasma Cells Predict Poor Survival in Multiple Myeloma
A recent study evaluated the impact of circulating plasma cells in patients with primary multiple myeloma on bortezomib-containing induction therapy.
Advertisement
PW QUIZ
Advertisement
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
